Effects of MDR-reversing agents on ADM and VCR cytotoxicity
| Treatment | IC501-a | ||
|---|---|---|---|
| KB-3-1 | KB-8-5 | C-A120 | |
| μM | |||
| ADM | 0.07 ± 0.00351-b (1)1-c | 2.93 ± 0.1320 (41.9) | 4.25 ± 0.4757 (60.7) |
| +Verapamil (3 μm) | 0.07 ± 0.0070 (1.00) | 0.56 ± 0.0163 (8.00) | 4.30 ± 0.4325 (61.4) |
| +Cepharanthine (3 μm) | 0.19 ± 0.0512 (2.71) | 0.41 ± 0.1261 (5.86) | 4.13 ± 0.1173 (59.0) |
| +Cepharanthine (5 μm) | 0.21 ± 0.0534 (3.00) | 0.16 ± 0.0283 (2.29) | 4.12 ± 0.3786 (58.9) |
| +PAK-104P (3 μm) | 0.06 ± 0.0198 (0.86) | 0.13 ± 0.0039 (1.86) | 1.56 ± 0.0658 (22.3) |
| +PAK-104P (10 μm) | 0.04 ± 0.0051 (0.57) | 0.13 ± 0.0020 (1.86) | 0.62 ± 0.0585 (8.86) |
| VCR | 0.54 ± 0.0240 (1) | 87.52 ± 2.6239 (162) | 47.23 ± 2.3792 (87.5) |
| +Verapamil (3 μm) | 0.53 ± 0.236 (0.98) | 5.66 ± 0.4779 (10.5) | 8.57 ± 1.0103 (15.9) |
| +Cepharanthine (3 μm) | 0.49 ± 0.0236 (0.91) | 1.98 ± 0.0861 (3.67) | 24.99 ± 0.9291 (46.38) |
| +Cepharanthine (5 μm) | 0.43 ± 0.0184 (0.80) | 0.86 ± 0.1204 (1.59) | 15.76 ± 0.6339 (29.2) |
| +PAK-104P (3 μm) | 0.38 ± 0.0107 (0.70) | 0.81 ± 0.0371 (1.50) | 1.71 ± 0.0563 (3.17) |
| +PAk-104P (10 μm) | 0.22 ± 0.0126 (0.41) | 0.48 ± 0.0219 (0.89) | 0.75 ± 0.0156 (1.39) |
| Melphalan | 28.85 ± 5.64 (1) | N.D. | 29.63 ± 3.22 (1.03) |
| +PAK-104P (10 μm) | 27.31 ± 2.19 (0.95) | N.D. | 27.71 ± 1.96 (0.96) |
| Cytosine arabinoside | 2.85 ± 0.12 (1) | N.D. | 2.91 ± 0.20 (1.02) |
| +PAK-104P (10 μm) | 2.50 ± 0.13 (0.89) | N.D. | 2.72 ± 0.17 (0.95) |
↵1-a Cell survival was determined by MTT assay.
↵1-b Values are mean of four experiments.
↵1-c Relative resistance (IC50 value for ADM or VCR of KB-3-1 with the reversing agents or KB-8-5 and C-A120 with and without the reversing agents was divided by IC50value for KB for ADM or VCR without the reversing agents).
N.D., not determined.